Part 2 Consents
In January, the Commission challenged Getinge AB’s proposed $865 million acquisition of rival Datascope Corporation as anticompetitive in the market for endoscopic vessel harvesting devices (EVHs). EVHs are used during coronary artery bypass graft surgery where a vein is removed from a patients leg or arm to replace a damaged or blocked coronary artery. According to the Commission’s complaint, the acquisition as proposed would substantially lessen competition in the relevant market, giving Getinge nearly a 90% market share and the ability to unilaterally increase prices while reducing the likelihood of innovation. The Commission issued a consent order remedying its concerns requiring that Datascope divest is EVH assets to Sorin Group USA, an FTC approved buyer, within 10 days of consummating the transaction.